Ken-ichiro Hata – Representative Director & Chairperson, Forum for Innovative Regenerative Medicine (FIRM), Japan

15.09.2020
Dr Ken-ichiro Hata, representative director and chairperson of Japan's Forum for Innovative Regenerative Medicine (FIRM) outlines the organisation's mandate, how Japan has been able to cultivate one of the world's most mature regenerative medicine ecosystems, and highlights key challenges including regulatory misalignment across Asia and the need for better manufacturing and commercialisation models.  
We are confident that 2020 and 2021 will be very relevant years for regenerative medicine in Japan
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Japan, Regenerative Medicine, FIRM, Cell & Gene Therapy, Association, Asia-Pacific

Related Interviews

Japan / Exclusive Conversation with Takeda's Japan Oncology Head Takafumi Horii

Experienced global leader Takafumi Horii explains the rationale behind returning to his home nation of Japan to head up Takeda’s Japan Oncology operations. Horii also touches on the significant burden…

Ryu Ogawa – CEO & Satoshi Tamaki – CSO, Molcure, Japan

Ryu Ogawa and Satoshi Tamaki of Japanese AI-powered drug discovery firm Molcure outline how their technology can supercharge the speed and efficiency of the drug discovery process as well as…

Yoji Yuki – CEO, UniBio Corporation

Yoji Yuki, CEO of Japanese regenerative medicine company UniBio, recalls the roots behind the venture and its plant-based technology. He also sets out his ambitions to expand and develop greater…

Related Articles

Top 10 Global Pharma Markets Ranking

Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more.  …

Japan / PMDA Chief Executive Yasuhiro Fujiwara on Regulatory Utilisation of RWD & RWE

Writing in the October edition of DIA’s Global Forum magazine, Chief Executive of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Yasuhiro Fujiwara outlines how his agency has begun to utilise…

Japan / COVID-19: Treatments, Vaccines & Remote Study Audits

Writing in the August edition of DIA’s Global Forum, Kotone Matsuyama of the Nippon Medical School gives a run-through of Japan’s response to the COVID-19 pandemic, from the organisation and communication…

Latest Report

Switzerland Pharma Report June 2021

Related Content

Japan
Regenerative Medicine
FIRM
Cell & Gene Therapy
Association
Asia-Pacific